Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review

Benchalak Maneeton,1 Narong Maneeton,1 Surinporn Likhitsathian,1 Pakapan Woottiluk,2 Punjaree Wiriyacosol,1 Vudhichai Boonyanaruthee,1 Manit Srisurapanont1 1Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; 2Psychiatric Nursing Division, Faculty of Nursing,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maneeton B, Maneeton N, Likhitsathian S, Woottiluk P, Wiriyacosol P, Boonyanaruthee V, Srisurapanont M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Escitalopram Duloxetine Efficacy Acceptability Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/2026a855f7864a32bf5c2cef725589dc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2026a855f7864a32bf5c2cef725589dc
record_format	dspace
spelling	oai:doaj.org-article:2026a855f7864a32bf5c2cef725589dc2021-12-02T03:38:33ZEscitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review1178-2021https://doaj.org/article/2026a855f7864a32bf5c2cef725589dc2018-08-01T00:00:00Zhttps://www.dovepress.com/escitalopram-vs-duloxetine-in-acute-treatment-of-major-depressive-diso-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Benchalak Maneeton,1 Narong Maneeton,1 Surinporn Likhitsathian,1 Pakapan Woottiluk,2 Punjaree Wiriyacosol,1 Vudhichai Boonyanaruthee,1 Manit Srisurapanont1 1Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; 2Psychiatric Nursing Division, Faculty of Nursing, Chiang Mai University, Chiang Mai, Thailand Background: Previous evidence indicated that efficacy of escitalopram (Esc) and duloxetine (Dul) was comparable in the treatment of major depressive disorder (MDD). Since such studies had small sample sizes, this study purposefully applied a systematic review to determine the efficacy, acceptability, and tolerability those antidepressants in treatment of MDD. Participants and methods: The following primary databases were searched in July 2017: Scopus, PubMed, CINAHL, and Cochrane Controlled Trials Register. Any randomized controlled trials (RCTs) of Esc comparison with Dul in the treatment of MDD were included in this review. The primary efficacy of outcome was the pooled mean-changed scores of the rating scales for the standardized rating scales for depression. Results: A total of 1,120 randomized subjects from 3 RCTs were collected for synthesis in the present meta-analysis. The mean-changed scores of the Hamilton Depression Rating Scale (HAMD) and Clinical Global Impression – Severity, overall response rate by the HAMD, and remission rate by the HAMD and Montgomery–Asberg Depression Rating Scale (MADRS) in the Esc- and Dul-treated groups showed no significant differences. However, the mean-changed score of the MARDS, mean-end scores of Clinical Global Impression – Improvement, and overall response by the MADRS in the Esc-treated group were greater than that of the Dul-treated group. Although the overall discontinuation rate had no significant differences between the 2 groups, the discontinuation rate due to adverse events in the Esc-treated group was greater than that of the Dul-treated group. Limitations: This review had limited eligible studies. Conclusion: This review indicated the efficacy in the acute treatment of Esc vs Dul varied relying on measurements across the studies. However, the tolerability of Esc was superior to Dul in acute MDD treatment. Therefore, selection between the 2 antidepressants may depend on the tolerability of MDD patients. Due to limited included studies in this review, more large-scale and well-defined RCTs in such patients should be carried out to determine these outcomes. Keywords: Hamilton Depression Rating Scale, HAMD, Montgomery–Asberg Depression Rating Scale, MADRS, efficacy, acceptability, tolerabilityManeeton BManeeton NLikhitsathian SWoottiluk PWiriyacosol PBoonyanaruthee VSrisurapanont MDove Medical PressarticleEscitalopramDuloxetineEfficacyAcceptabilityNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 14, Pp 1953-1961 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Escitalopram Duloxetine Efficacy Acceptability Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Escitalopram Duloxetine Efficacy Acceptability Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Maneeton B Maneeton N Likhitsathian S Woottiluk P Wiriyacosol P Boonyanaruthee V Srisurapanont M Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
description	Benchalak Maneeton,1 Narong Maneeton,1 Surinporn Likhitsathian,1 Pakapan Woottiluk,2 Punjaree Wiriyacosol,1 Vudhichai Boonyanaruthee,1 Manit Srisurapanont1 1Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; 2Psychiatric Nursing Division, Faculty of Nursing, Chiang Mai University, Chiang Mai, Thailand Background: Previous evidence indicated that efficacy of escitalopram (Esc) and duloxetine (Dul) was comparable in the treatment of major depressive disorder (MDD). Since such studies had small sample sizes, this study purposefully applied a systematic review to determine the efficacy, acceptability, and tolerability those antidepressants in treatment of MDD. Participants and methods: The following primary databases were searched in July 2017: Scopus, PubMed, CINAHL, and Cochrane Controlled Trials Register. Any randomized controlled trials (RCTs) of Esc comparison with Dul in the treatment of MDD were included in this review. The primary efficacy of outcome was the pooled mean-changed scores of the rating scales for the standardized rating scales for depression. Results: A total of 1,120 randomized subjects from 3 RCTs were collected for synthesis in the present meta-analysis. The mean-changed scores of the Hamilton Depression Rating Scale (HAMD) and Clinical Global Impression – Severity, overall response rate by the HAMD, and remission rate by the HAMD and Montgomery–Asberg Depression Rating Scale (MADRS) in the Esc- and Dul-treated groups showed no significant differences. However, the mean-changed score of the MARDS, mean-end scores of Clinical Global Impression – Improvement, and overall response by the MADRS in the Esc-treated group were greater than that of the Dul-treated group. Although the overall discontinuation rate had no significant differences between the 2 groups, the discontinuation rate due to adverse events in the Esc-treated group was greater than that of the Dul-treated group. Limitations: This review had limited eligible studies. Conclusion: This review indicated the efficacy in the acute treatment of Esc vs Dul varied relying on measurements across the studies. However, the tolerability of Esc was superior to Dul in acute MDD treatment. Therefore, selection between the 2 antidepressants may depend on the tolerability of MDD patients. Due to limited included studies in this review, more large-scale and well-defined RCTs in such patients should be carried out to determine these outcomes. Keywords: Hamilton Depression Rating Scale, HAMD, Montgomery–Asberg Depression Rating Scale, MADRS, efficacy, acceptability, tolerability
format	article
author	Maneeton B Maneeton N Likhitsathian S Woottiluk P Wiriyacosol P Boonyanaruthee V Srisurapanont M
author_facet	Maneeton B Maneeton N Likhitsathian S Woottiluk P Wiriyacosol P Boonyanaruthee V Srisurapanont M
author_sort	Maneeton B
title	Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
title_short	Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
title_full	Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
title_fullStr	Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
title_full_unstemmed	Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
title_sort	escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/2026a855f7864a32bf5c2cef725589dc
work_keys_str_mv	AT maneetonb escitalopramvsduloxetineinacutetreatmentofmajordepressivedisordermetaanalysisandsystematicreview AT maneetonn escitalopramvsduloxetineinacutetreatmentofmajordepressivedisordermetaanalysisandsystematicreview AT likhitsathians escitalopramvsduloxetineinacutetreatmentofmajordepressivedisordermetaanalysisandsystematicreview AT woottilukp escitalopramvsduloxetineinacutetreatmentofmajordepressivedisordermetaanalysisandsystematicreview AT wiriyacosolp escitalopramvsduloxetineinacutetreatmentofmajordepressivedisordermetaanalysisandsystematicreview AT boonyanarutheev escitalopramvsduloxetineinacutetreatmentofmajordepressivedisordermetaanalysisandsystematicreview AT srisurapanontm escitalopramvsduloxetineinacutetreatmentofmajordepressivedisordermetaanalysisandsystematicreview
_version_	1718401654053666816

Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review

Ejemplares similares